Johnson & Johnson Launches Head-to-Head Phase III TRILOGY-5 Trial of First-in-Class Trispecific Antibody Ramantamig (JNJ-79635322) vs. Teclistamab in Relapsed/Refractory Multiple Myeloma

Local time on April 8Recently, the ClinicalTrials website showed that Johnson & Johnson registered aComparison of JNJ-79635322（Ramantamig）And Teclistamab(Terlipressin)Having received 1 to 3 lines of prior treatment(Including anti-CD38 antibody, lenalidomide)Efficacy in patients with relapsed or refractory multiple myelomaPhase III TRIlogy-5 Study（NCT07518186）。

Source:ClinicalTrials Official Website

The study plans to enroll700 subjects, RandomGroup AcceptanceJNJ-79635322 and teclistamab treatment until disease progression or intolerable toxicity occurs.

The primary endpoint isComplete Remission（CR）Or better, as well as progression-free survival（PFS）. Secondary endpoints include overall response rate（ORR）, Duration of Relief（DoR）, Very good partial remission（VGPR）Or better, minimal residual disease（MRD）Negative complete remission, etc.

The study is scheduled to start on June 9, 2026, and end on December 8, 2032.

Ramantamig is a next-generation tri-specific antibody developed by Johnson & Johnson.TargetedBCMA, GPRC5D, and CD3In December 2025, Johnson & Johnson launched the first Phase III clinical trial, Trilogy-4, for this product, aiming to compare it with Teclista.mab in the pastHave received at least 3 lines of treatment(Including proteasome inhibitors, immunomodulators, and anti-CD38 antibodies)Efficacy in RRMM Patients.

Insight database shows that currently, globally, there are a total of6 CD3/BCMA/GPRC5D Trispecific AntibodiesEntering the clinical stage, except for Johnson & Johnson'sApart from JNJ-79635322, all others are produced in China, coming respectively from Tian Guangshi.（MBS314、MBS314 Subcutaneous Injection）, Innovent Biologics（IBI3003）、Qilu Pharmaceutical（QLS4131）And Simcere Pharmaceutical（SIM0500）。

Source:Insight Database

Cover Source:Corporate Logo

Disclaimer:This article is for information sharing only and does not represent the position or viewpoint of Insight. It also does not recommend or introduce any treatment plans. If necessary, please consult and contact正规医疗机构.

Editor: Crescent

PR Article Coordination: WeChat insightxb